Inclusion Criteria:

- Patients >= 18 years old

- Patients with colon or rectal carcinoma histologically proven

- Patients with metastases (synchronous or metachronous)

- Patients with associated extra-hepatic disease (asymptomatic primary tumor or
extra-hepatic metastases)

- Performance status (World Health Organization [WHO]) = 0, 1, or 2

- Life expectancy >= 3 months

- Patients with normal haematological, kidney, and liver parameters (PNN > 1.5 x
10^9/L, platelets > 100 10^9/L, total bilirubin <= 1.25 x upper limit of normal
(ULN), ASAT/ALAT <= 5 x ULN, creatinaemia <= 135 µmol/L (1.5 mg/dL)

- No cardiac or coronary insufficiency untreated

- At least 4 weeks between surgery and study beginning

- Patients can have a biopsy of the hepatic lesion identified by ultrasound.

- Informed consent signed.

Exclusion Criteria:

- Patients with symptomatic tumors (colon or rectal)

- Patients with others tumors not cured

- Patients who cannot be treated by 5-fluorouracil (5-FU) and/or irinotecan because of
special medical conditions or other serious disease.

- Patients who participated in another clinical trial since less than 30 days

- Pregnancy or breast-feeding women

- Patients who cannot be treated because of active infection or other serious disease.